Anticoagulation Therapy Considerations in Factor VII Deficiency

Area of Science:

• Hematology
• Rare bleeding disorders
• Pharmacology

Background:

• Factor VII (FVII) deficiency is a rare bleeding disorder affecting ~1 in 500,000 people.
• Warfarin inhibits FVII synthesis, posing risks for patients with FVII deficiency.
• Limited literature exists on warfarin use in FVII deficiency due to contraindications.

Purpose of the Study:

• To report a successful re-challenge of warfarin therapy in a patient with FVII deficiency.
• To evaluate the safety and efficacy of warfarin in this patient population.
• To explore alternative anticoagulation strategies for FVII deficiency patients with atrial fibrillation.

Main Methods:

• A 70-year-old female patient with FVII deficiency was initially switched from warfarin due to bleeding.
• Warfarin therapy was re-attempted years later under different hematological guidance.
• FVII activity and international normalized ratio (INR) were monitored over 9 months.

Main Results:

• The patient tolerated re-challenged warfarin therapy for 9 months without bleeding events.
• FVII activity remained within an acceptable range.
• Achieved and maintained international normalized ratio (INR) within the target range (1.5-2.0).

Conclusions:

• Warfarin re-challenge can be successful in select FVII deficiency patients.
• Direct oral anticoagulants (DOACs) may be safer alternatives to warfarin.
• DOACs could reduce bleeding risks for FVII deficient patients with atrial fibrillation, preventing thromboembolic stroke.